Rebisufligene etisparvovec

N/A

Report date: 2026/02/04 17:37:40

Base Information

Drug NameRebisufligene etisparvovec
Drug Alias NameABX-102ABO-102scAAV9.U1a.hSGSHABX-BAAV-SGSH +[9] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionGene transferenceN-sulphoglucosamine sulphohydrolase stimulants
TargetsN-sulphoglucosamine sulphohydrolase
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSpain
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesUltragenyx Pharmaceutical IncAbeona Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMucopolysaccharidosis III
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A